Hemostemix (CVE:HEM) Stock Price Down 11.1% – Should You Sell?
by Scott Moore · The Cerbat GemHemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was down 11.1% during trading on Monday . The stock traded as low as C$0.08 and last traded at C$0.08. Approximately 155,328 shares changed hands during trading, an increase of 75% from the average daily volume of 88,872 shares. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The firm has a market capitalization of C$16.02 million, a price-to-earnings ratio of -3.15 and a beta of 1.25. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The business has a 50-day moving average price of C$0.09 and a two-hundred day moving average price of C$0.10.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.